• +1-646-491-9876
    • +91-20-67278686

    Search

    Dyskinesia Pipeline Review H1 2017

    Dyskinesia Pipeline Review H1 2017

    • Report Code ID: RW0001799304
    • Category Pharmaceuticals
    • No. of Pages 157
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Dyskinesia - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H1 2017, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

    Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 11, 6, 18 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

    Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Dyskinesia - Overview 8
    Dyskinesia - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 13
    Products under Development by Companies 14
    Products under Development by Universities/Institutes 17
    Dyskinesia - Therapeutics Assessment 18
    Assessment by Target 18
    Assessment by Mechanism of Action 21
    Assessment by Route of Administration 24
    Assessment by Molecule Type 26
    Dyskinesia - Companies Involved in Therapeutics Development 28
    Adamas Pharmaceuticals Inc 28
    Addex Therapeutics Ltd 28
    Advicenne SA 29
    Astraea Therapeutics LLC 29
    Avanir Pharmaceuticals Inc 30
    Bionomics Ltd 30
    Catalyst Biosciences Inc 31
    Catalyst Pharmaceuticals Inc 31
    Cavion LLC 32
    Clevexel Pharma SAS 32
    EpiVax Inc 33
    Heptares Therapeutics Ltd 33
    Ipsen SA 34
    Merz Pharma GmbH & Co KgaA 34
    Neurim Pharmaceuticals Ltd 35
    Neurocrine Biosciences Inc 35
    Neurolixis Inc 36
    Osmotica Pharmaceutical Corp 36
    Phenomenome Discoveries Inc 37
    Sage Therapeutics Inc 37
    SciFluor Life Sciences LLC 38
    SOM Biotech SL 38
    Synchroneuron Inc 39
    Teva Pharmaceutical Industries Ltd 39
    Dyskinesia - Drug Profiles 40
    (dextromethorphan + quinidine sulfate) - Drug Profile 40
    A-2M13677 - Drug Profile 45
    abobotulinumtoxinA - Drug Profile 46
    acamprosate calcium SR - Drug Profile 50
    amantadine hydrochloride ER - Drug Profile 52
    amantadine hydrochloride ER - Drug Profile 61
    AT-127 - Drug Profile 62
    AT-326 - Drug Profile 63
    AT-403 - Drug Profile 64
    befiradol - Drug Profile 65
    brexanolone - Drug Profile 67
    CPP-115 - Drug Profile 76
    CVXL-0107 - Drug Profile 81
    CX-8998 - Drug Profile 82
    cycloserine - Drug Profile 83
    deutetrabenazine - Drug Profile 84
    dipraglurant IR - Drug Profile 90
    Drug for Dyskinesia - Drug Profile 95
    Drug for Tardive Dyskinesia - Drug Profile 96
    Drugs for Dyskinesia - Drug Profile 97
    Gene Therapy to Inhibit TRH for Dyskinesia - Drug Profile 98
    HTL-14242 - Drug Profile 99
    incobotulinumtoxin A - Drug Profile 100
    IRL-790 - Drug Profile 104
    JM-010 - Drug Profile 105
    MLR-1019 - Drug Profile 107
    NBI-640756 - Drug Profile 108
    Neu-120 - Drug Profile 109
    Neu-240 - Drug Profile 110
    NXN-413 - Drug Profile 111
    NXN-613 - Drug Profile 112
    onabotulinumtoxinA - Drug Profile 113
    PEUN-3 - Drug Profile 114
    PPI-1011 - Drug Profile 115
    RNAi Gene Therapy to Inhibit NURR1 for Dyskinesia - Drug Profile 116
    SAGE-217 - Drug Profile 117
    SK-609 - Drug Profile 120
    Small Molecule for Dyskinesia - Drug Profile 121
    Small Molecule for Dyskinesia - Drug Profile 122
    Small Molecules for Neurodegenerative Disease - Drug Profile 123
    Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile 124
    Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 125
    Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 126
    Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile 127
    Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile 128
    SOM-3355 - Drug Profile 129
    TC-8831 - Drug Profile 130
    tetrabenazine - Drug Profile 131
    valbenazine tosylate - Drug Profile 132
    Dyskinesia - Dormant Projects 139
    Dyskinesia - Discontinued Products 141
    Dyskinesia - Product Development Milestones 142
    Featured News & Press Releases 142
    Appendix 153
    Methodology 153
    Coverage 153
    Secondary Research 153
    Primary Research 153
    Expert Panel Validation 153
    Contact Us 153
    Disclaimer 154

    List of Tables

    Number of Products under Development for Dyskinesia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Dyskinesia - Pipeline by Adamas Pharmaceuticals Inc, H1 2017
    Dyskinesia - Pipeline by Addex Therapeutics Ltd, H1 2017
    Dyskinesia - Pipeline by Advicenne SA, H1 2017
    Dyskinesia - Pipeline by Astraea Therapeutics LLC, H1 2017
    Dyskinesia - Pipeline by Avanir Pharmaceuticals Inc, H1 2017
    Dyskinesia - Pipeline by Bionomics Ltd, H1 2017
    Dyskinesia - Pipeline by Catalyst Biosciences Inc, H1 2017
    Dyskinesia - Pipeline by Catalyst Pharmaceuticals Inc, H1 2017
    Dyskinesia - Pipeline by Cavion LLC, H1 2017
    Dyskinesia - Pipeline by Clevexel Pharma SAS, H1 2017
    Dyskinesia - Pipeline by EpiVax Inc, H1 2017
    Dyskinesia - Pipeline by Heptares Therapeutics Ltd, H1 2017
    Dyskinesia - Pipeline by Ipsen SA, H1 2017
    Dyskinesia - Pipeline by Merz Pharma GmbH & Co KgaA, H1 2017
    Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017
    Dyskinesia - Pipeline by Neurocrine Biosciences Inc, H1 2017
    Dyskinesia - Pipeline by Neurolixis Inc, H1 2017
    Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp, H1 2017
    Dyskinesia - Pipeline by Phenomenome Discoveries Inc, H1 2017
    Dyskinesia - Pipeline by Sage Therapeutics Inc, H1 2017
    Dyskinesia - Pipeline by SciFluor Life Sciences LLC, H1 2017
    Dyskinesia - Pipeline by SOM Biotech SL, H1 2017
    Dyskinesia - Pipeline by Synchroneuron Inc, H1 2017
    Dyskinesia - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
    Dyskinesia - Dormant Projects, H1 2017
    Dyskinesia - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Dyskinesia - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Dyskinesia, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Adamas Pharmaceuticals Inc
    Addex Therapeutics Ltd
    Advicenne SA
    Astraea Therapeutics LLC
    Avanir Pharmaceuticals Inc
    Bionomics Ltd
    Catalyst Biosciences Inc
    Catalyst Pharmaceuticals Inc
    Cavion LLC
    Clevexel Pharma SAS
    EpiVax Inc
    Heptares Therapeutics Ltd
    Ipsen SA
    Merz Pharma GmbH & Co KgaA
    Neurim Pharmaceuticals Ltd
    Neurocrine Biosciences Inc
    Neurolixis Inc
    Osmotica Pharmaceutical Corp
    Phenomenome Discoveries Inc
    Sage Therapeutics Inc
    SciFluor Life Sciences LLC
    SOM Biotech SL
    Synchroneuron Inc
    Teva Pharmaceutical Industries Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//dyskinesia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//dyskinesia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//dyskinesia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments